The Week

Intuitive Surgical (ISRG) closed at $369.15, up 0.67% from the prior Friday’s close of $366.70. The S&P 500 fell 0.8% over the same stretch, so the stock outperformed the benchmark by about 1.47 percentage points. The week started soft: Tuesday saw a drop to $347.52 intraday and a close at $350.16. Wednesday and Thursday stabilised, with Thursday touching a low of $345.25 before recovering. Friday opened higher and pushed to a high of $374.48, finishing near the top of the week’s range as the daily swing widened again.

Key Events

Company news this week centred on insider selling. Executive Vice President and Chief Manufacturing and Supply Chain Officer Mark Brosius disclosed two small common-share sales on 10 and 12 September, worth about $24,222 and $17,138 respectively. These were routine filings and did not appear to move the stock. The shares fell 4.38% on 8 September as health care and financials led the broader pullback, and the stock lagged peers that day. Momentum flipped later in the week, and on Friday ISRG outperformed competitors. On 12 September, media reported Johnson & Johnson is betting on Ottava to challenge Intuitive Surgical in robotic surgery, while another piece noted a $1,000 investment in ISRG a decade ago would be worth substantially more today. The picture is one of continued market leadership with rising competitive attention.

Analyst Ratings

As of 11 September, 32 brokers cover the stock: 17 rate it buy, 7 overweight, 7 hold, and 1 sell. The consensus rating is buy, with a consensus target of $476.34483, about 29.04% above the current price. Targets range from $324 to $685, a wide spread. Intuitive Surgical ranks first among 142 names in the medical device industry.

The Week Ahead

Macro data picks up next week. The New York Fed manufacturing index lands on Tuesday 15 September. Wednesday 16 September brings retail sales, retail sales ex-autos, retail control, import prices, the NAHB housing market index, and the EIA weekly crude and Cushing inventories. These releases will influence risk appetite across health care and the broader market, which may shape the stock’s relative performance.

In Short

ISRG dipped early in the week before closing near the top of its range, beating the S&P 500 by roughly 1.47 percentage points. Brokers remain constructive: consensus is buy, with a target about 29% above spot and a first-place industry ranking, though the $324 to $685 target span points to wide disagreement. Externally, Johnson & Johnson’s Ottava push keeps the robotic-surgery competition story alive. Looking ahead, whether the stock can hold above the upper end of its $345.25 to $374.48 weekly range amid a dense macro calendar, and how the competitive narrative develops, are the two threads to watch.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.